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WU	 polyomavirus	 (WUPyV)	 and	 KI	 polyomavirus	  
(KIPyV)	are	novel	human	polyomaviruses.	They	were	origi-
nally	identified	in	human	respiratory	secretions,	but	the	ex-
tent of human infection caused by these viruses has not 
been described to date. To determine the seroepidemiology 
of	WUPyV	and	KIpyIV,	we	used	an	ELISA	to	screen	serum	
samples from 419 patients at the St. Louis Children’s Hospi-
tal	and	Barnes-Jewish	Hospital	during	2007–2008.	The	age-
stratified	deidentified	samples	were	examined	for	antibodies	
to	the	major	capsid	proteins	of	WUPyV	and	KIPyV.	Sero-
positivity for each virus was similar; antibody levels were 
high in the youngest age group (<6 months), decreased to 
a nadir in the next age group (6 to <12 months), and then 
steadily increased with subsequent age groups, eventually 
reaching a plateau of ≈80%	for	WUPyV	and	≈70%	for	KIPyV.	  
These	results	demonstrate	that	both	KIPyV	and	WUPyV	
cause widespread infection in the human population.
W
U polyomavirus (WUPyV) (1) and KI polyomavirus 
(KIPyV) (2) are newly described human polyomavi-
ruses most closely related to JC virus (JCV) and BK virus 
(BKV). JCV and BKV are human pathogens that common-
ly infect the population. In the United States, seropositivity 
rates of 44%–75% for JCV and 63%–80% for BKV have 
been reported (3,4). Current models suggest that initial in-
fection by BKV and JCV occurs asymptomatically during 
childhood; latency may establish in the kidneys and may 
reactivate during immune suppression. JCV causes a fatal 
demyelinating  disease  of  progressive  multifocal  leuko- 
encephalopathy in immunocompromised persons (5). BKV 
is associated with a number of renal and urinary tract infec-
tions including tubular nephritis, which can lead to allograft 
failure in renal transplant recipients (6), and hemorrhagic 
cystitis in hematopoietic stem cell transplant recipients (7). 
Another human polyomavirus, Merkel cell polyomavirus, 
was recently discovered and has tentatively been linked to 
Merkel cell carcinoma (8).
For KIPyV and WUPyV, neither disease association 
nor extent of infection in the human population has been 
established. Both viruses were originally identified in spec-
imens from patients with respiratory illnesses of unknown 
etiology. Subsequent studies found WUPyV and KIPyV in 
the respiratory tract of patients with and without respira-
tory signs and symptoms (9–11), in fecal samples (12,13), 
and in lymphoid tissue from immunocompromised persons 
(14). Reported prevalence rates are 1%–9% for WUPyV 
and 0.5%–3% for KIPyV (1,2,12,13). The severity of dis-
eases caused by BKV and JCV (5,6,15) raises the question 
of whether WUPyV and KIPyV can cause human disease. 
As a step toward determining the potential pathogenicity of 
these viruses, we developed serologic assays to assess the 
extent of infection by WUPyV and KIPyV in humans.
Materials and Methods
Plasmid Constructs, Protein Expression, and Purifica-
tion
Genes encoding the major capsid proteins, KIPyV vi-
ral protein 1 (VP1) and WUPyV VP1, were cloned into the 
Gateway vector pENTR/SD/D-TOPO (Invitrogen, Carlsbad, 
CA, USA) by PCR from clinical samples. The primers were 
as  follows:  5′-CACCATGAGCTGCACCCCGT-3′  (for-
ward) and 5′-ATACATTCACTTTGAATTTTGTTGAG-3′ 
(reverse)  for  the  KIPyV  VP1  PCR  and  5′-CACCA 
TGGCCTGCACAGCAAAGCCAGCC-3′  (forward)  and 
5′-TTATCCTTGTGTGTTTAGTATTGG-3′  (reverse)  for 
the WUPyV VP1 PCR. Sequencing analysis showed that 
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the KIPyV VP1 gene cloned was identical to that of the 
Brisbane 002 strain (GenBank accession no. ABR68682), 
except for 2 silent nucleotide mutations at positions 537 
and  1005.  For  WUPyV,  the  gene  encoding  VP1  was 
identical to that of the B0 strain (GenBank accession no. 
ABQ09289). Positive clones containing the inserts were 
then transferred into the p-DEST15 plasmid (Invitrogen) 
by LR-homologous recombination to generate N-terminal–
tagged  glutathione  S-transferase  (GST)–WUPyV  VP1 
(plasmid  NN003)  and  GST-KIPyV  VP1  (NN006)  con-
structs.  N-terminal–tagged  GST-VP1s  from  BKV,  JCV, 
and simian virus 40 (SV40) were generously provided by 
Michael Pawlita (16), and GST-tagged microneme (Mic) 
protein encoded by Toxoplasma gondii was provided by 
David  Sibley.  VP1  was  expressed  in  BL21(DE3)pLysS 
bacterial cells and affinity purified under native conditions 
by using the BugBuster GST-Bind Purification Kit (Nova-
gen, Darmstadt, Germany) according to the manufacturer’s 
suggested protocol.
Polyacrylamide Gel Electrophoresis and Western Blot 
Analysis
Proteins were separated by electrophoresis in 4%–15% 
polyacrylamide gradient gels (no. 161-1122; BioRad, Her-
cules,  CA,  USA)  by  using  Tris/glycine/sodium  dodecyl 
sulfate  (SDS)  buffer  (no.  161–0732;  BioRad).  The  pro-
teins were then either stained with Coomassie brilliant blue 
or  transferred  to  a  polyvinylidene  difluoride  membrane 
(no. LC2002; Invitrogen) for Western blot immunoassay. 
Membranes were blocked with 5% nonfat milk in phos-
phate-buffered saline with Tween 20 (PBS-T) for 1 h, then 
incubated with the primary antibody followed by peroxi-
dase-conjugated Protein A/G (no. 32490; Pierce Biotech-
nology, Rockford, IL, USA). The proteins were visualized 
by using a SuperSignal West Pico kit (no. 34077; Thermo 
Scientific,  Rockford,  IL,  USA).  Membranes  that  were 
probed >1× were stripped with Restore Western Blot Strip-
ping Buffer (no. 21059; Thermo Scientific) and reblocked 
with 5% nonfat milk in PBS-T between immunoassays.
Antibody Production
WUPyV VP1 peptide sequence (TAKPGRSPRSQP-
TRC)  and  KIPyV  VP1  peptide  sequence  (CRPQKRL-
TRPRSQV) were each synthesized and injected into rab-
bits to produce polyclonal antibodies against WUPyV VP1 
and KIPyV VP1 (service provided by GenScript, Piscat-
away, NJ, USA). Rabbit hyperimmune antiserum against 
the virus-like particles of BKV (BKVLP), JCV (JCVLP), 
or SV40 were kindly provided by Joakim Dillner (17). Per-
oxidase-conjugated goat anti-human immunoglobulin (Ig) 
G, (no. 31413) peroxidase-conjugated goat anti-rabbit IgG 
(no. 31463), and mouse anti-GST (no. 30001) antibodies 
were obtained from Thermo Scientific. 
Serum Sample Analyses
We  analyzed  419  deidentified  serum  samples  from 
patients 1 day to 79 years of age at St. Louis Children’s 
Hospital or Barnes-Jewish Hospital in St. Louis, Missouri, 
USA, from November 2007 through October 2008 for anti-
bodies against VP1 of WU and KI polyomaviruses. Serum 
samples were kindly provided by Greg Storch (St. Louis 
Children’s  Hospital)  and  Mitchell  Scott  (Barnes-Jewish 
Hospital). The patients were age stratified (Table), and 30 
samples were used for each age group, except for the group 
6 to <12 months, for which 29 samples were available. Col-
lection of samples and clinical data were approved by the 
Human Research Protection Office of Washington Univer-
sity in St. Louis, School of Medicine.
ELISA
To develop the WU ELISA and the KI ELISA, we 
used as positive controls 2 convalescent serum samples 
from a child known to be infected with WUPyV and rabbit 
hyperimmune serum for WUPyV VP1 or KIPyV VP1, and 
we used as negative controls rabbit preimmune serum and 
serum derived from pediatric patients (<3 years of age). 
The optimal coating concentration of VP1, serum dilution, 
secondary conjugate dilution, and blocking reagent were 
determined by checkerboard titration experiments. Briefly, 
purified GST-VP1 (0.12 μg/well) was coated overnight at 
4°C in PBS, pH 7.2, by using Maxisorp 96-well microtiter 
plates (Nunc, Naperville, IL, USA). Wells were washed 3× 
with PBS containing 0.05% PBS-T and blocked with 2% 
nonfat milk in PBS-T (PBS-TM) for 2 h at room tempera-
ture. Human serum samples (60 μL), diluted 1:100 in PBS-
TM, were added to each well in triplicate and incubated for 
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Table. Age distribution of patients (419 samples) who were 
seropositive	for	WUPyV,	KIPyV,	or	both,	St.	Louis,	Missouri,	
USA,	November	2007–October	2008*	
No.	(%)	seropositive	
Age group KIPyV	VP1	 WUPyV	VP1	 Both
<6 mo 13 (43.3) 25 (83.3) 13 (43.3)
6 mo–<1 y  7 (24.1) 13 (44.8) 7 (24.1)
1 y 12 (40) 18 (60) 10 (33.3)
2 y 13 (43.3) 18 (60) 10 (33.3)
3 y 15 (50) 17 (56.7) 10 (33.3)
4 y 22 (73.3) 20 (66.7) 16 (53.3)
5 y 28 (93.3) 26 (86.7) 24 (80)
6–8 y 26 (86.7) 27 (90) 24 (80)
9–12 y 30 (100) 27(90) 27 (90)
13–19 y 28 (93.3) 28 (93.3) 27 (90)
20–34 y 21 (70) 30 (100) 21(70)
35–49 y 22 (73.3) 29 (96.7) 22 (73.3)
50–64 y 19 (63.3) 24 (80) 19 (63.3)
65–79 y 22 (73.3) 28 (93.3) 22 (73.3)
Total 278 (66.3) 330 (78.7) 252 (60.1)
*WUPyV,	WU	polyomavirus;	KIPyV,	KI	polyomavirus;	WUPyV	VP1,	
WUPyV	viral	protein	1;	KIPyV	VP1,	KIPyV	viral	protein	1.	Serologic Evidence of WU and KI Polyomaviruses
4 h (or overnight) at 4°C. The plates were washed 6× with 
PBS-T, and a peroxidase-conjugated, secondary anti-IgG 
antibody, diluted 1:40,000 in PBS-TM, was added and in-
cubated at 37°C for 2 h. After another washing step, plates 
were developed by adding peroxidase substrate tetramethyl 
benzidine (no. 34028; Thermo Scientific) for 15 min at room 
temperature. The reactions were stopped with H2SO4, and 
the absorbance was measured at 450 nm. For the blocking 
assays, serum samples were preincubated overnight at 4°C 
with, either singly or together in different combinations as 
indicated, recombinant GST-BKVP1, GST-JCVP1, GST-
KIPyV VP1, GST-SV40VP1, GST-WUPyV VP1, or an 
unrelated GST-Mic encoded by Toxoplasma gondii (at 0.6 
μg each, in solution), or in the blocking buffer alone. The 
ELISA was then used as described above.
Cutoff Value and Statistical Analysis
To calculate a cutoff value for the WU ELISA, we used 
31 pediatric serum samples that gave signals below that of 
rabbit preimmune serum. Samples with absorbance inten-
sity >3 SDs above the mean of these 31 samples (0.404 ± 
0.103 SD) were considered positive. A parallel set of 31 
negative samples (mean 0.286 ± 0.095 SD) were used to 
calculate a cutoff value for the KI ELISA. For each WU 
ELISA 96-well plate, the same negative control sample (se-
rum from a 3-month-old child previously considered nega-
tive by initial ELISA experiments) and the same positive 
control sample (convalescent-phase serum from a patient 
previously found to be WU positive) were used to control 
for interplate variations. The cutoff value for percentage 
coefficient of variation of these 2 control samples was set 
<30%, as described by Jacobson (18). All blank wells had 
absorbance values <0.1.
Results
WUPyV VP1 and KIPyV VP1 Proteins as  
Target Antigens in ELISAs
WUPyV VP1 and KIPyV VP1 were expressed in bacteria 
as N-terminal, GST-tagged fusion proteins and subsequently 
purified by using glutathione-affinity chromatography. We 
used SDS polyacrylamide gel electrophoresis coupled with 
Coomassie blue staining to analyze the production and puri-
fication of the recombinant proteins (Figure 1, panel A). The 
purified GST-WUPyV VP1 or GST-KIPyV VP1 was then 
used as the capture antigen in ELISA to detect antibodies 
against WUPyV VP1 or KIPyV VP1, respectively.
The results of a WU ELISA using WU-hyperimmune 
rabbit serum and WU-positive human convalescent-phase 
serum are shown in Figure 1, panel B. Both the rabbit and 
human  serum  samples  gave  strong  signals,  which  were 
effectively inhibited by preincubation with soluble GST-
WUPyV VP1. By contrast, preincubation with GST alone 
had only marginal effects on the ELISA signal intensity. 
An ELISA performed on a GST-KIPyV VP1 coated plate 
using KI-hyperimmune rabbit serum also showed similar 
KI-specific binding activity (data not shown).
Detection of Antibodies against WUPyV VP1  
and KIPyV VP1 in Human Serum Samples
Of the 419 serum samples analyzed, a representative 
WU ELISA result of 29 serum samples in the 3-year age 
group is shown in Figure 2, panel A. A range of absorbance 
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Figure	 1.	 ELISA	 using	 WU	 polyomavirus	 (WUPyV)	 viral	 protein	
1	(VP1)	or	KI	polyomavirus	(KIPyV)	VP1	as	the	target	antigen.	
A)  Coomassie  blue  staining  of  a  sodium  dodecyl  sulfate–
polyacryliamide gel that contains bacterially expressed glutathione 
S-transferase	 (GST)–KIPyV	 VP1	 and	 GST–WUPyV	 VP1	 before	
and	 after	 glutathione-affinity	 purification.	 B)	 ELISA	 using	 rabbit	
hyperimmune serum and human WU polyomavirus convalescent-
phase serum preincubated with buffer alone, GST protein, or GST–
WUPyV	VP1.	Error	bars	indicate	mean	and	SD.	RESEARCH
intensities were observed; 17 samples were above the cut-
off value. In a parallel KI ELISA conducted on this same 
set of serum samples, using rabbit serum immunized with a 
synthetic KIPyV VP1 peptide as positive control, 15 sam-
ples were considered ELISA positive (Figure 2, panel B).
Specificity of VP1-based WU ELISAs and KI ELISAs
WUPyV VP1 shares 65% amino acid identity with 
KIPyV  VP1  and  more  limited  similarity  with  JCVP1 
(27%), BKVP1 (28%), and SV40VP1 (28%) (1). Previ-
ous serologic studies demonstrated that antibodies against 
VP1 from BKV, JCV, and SV40 polyomaviruses were 
cross-reactive with antigens from all 3 of these viruses 
(4,19). To assess the specificity of the WU ELISA and KI 
ELISA, we expressed and purified GST-tagged VP1 from 
BKV, JCV, and SV40 and performed blocking ELISAs 
as described above. Figure 3, panel A, shows a blocking 
WU ELISA of 3 serum samples that had been preincu-
bated with, either singly or together in different combi-
nations,  GST-BKVP1,  GST-JCVP1,  GST-KIPyV  VP1, 
GST-SV40VP1, and GST-WUPyV VP1; with an unre-
lated GST-Mic protein; or with the blocking buffer alone. 
Two WU-positive samples, C09 and C56, had absorbance 
values reduced to some extent after preincubation with 
different recombinant proteins. However, only when pre-
incubated with the GST-WUPyV VP1 itself was the ELI-
SA signal intensity strongly reduced; C56 was reduced by 
83.5% and C09 by 79.6% compared with the buffer-alone 
samples. Of 34 randomly selected WU ELISA–positive 
samples tested, 32 showed inhibition levels >50% in the 
presence of soluble GST-WUPyV VP1. The 2 exceptions, 
A04 and A43, had limited inhibition of 42.5% and 36%, 
respectively. For these 2 samples, further dilution of the 
human serum enabled soluble GST-WUPyV VP1 to re-
duce the ELISA absorbance intensity by >50%, suggest-
ing perhaps that high titers of antibodies against WUPyV 
VP1 were present in these 2 samples (data not shown). To 
define the specificity of the KI ELISA, we preincubated 
ELISA-positive  samples  with  soluble  GST-Mic,  GST-
WUPyV VP1, GST-KIPyV VP1, or the buffer alone. Fig-
ure 3, panel B, shows blocking results of 5 representative 
KI-positive samples.  In each example, only preincuba-
tion with soluble GST-KIPyV VP1 substantially reduced 
the absorbance value, indicating the presence of specific 
antibodies against KIPyV VP1 in these samples.
1202	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	15,	No.	8,	August	2009
Figure  2.  ELISA  results  from  3-year  age  group.   A)  29  serum 
samples  in  the  3-year  age  group  were  assayed  for  antibodies 
against WU polyomavirus viral protein 1. B) KI polyomavirus ELISA 
results from the same 29 serum samples. The cutoff values for WU 
ELISA (0.713) and KI ELISA (0.572) are represented by dashed 
lines; –, negative control serum; +, positive control serum. Error 
bars indicate mean and SD.
Figure 3. Effects of preincubation of polyomavirus viral protein 1 on 
WU ELISA and KI ELISA. Samples were preincubated with single 
or multiple proteins in different combinations or with the blocking 
buffer alone. Shown are results of blocking WU ELISA (A) and 
blocking KI ELISA (B) of representative serum samples. Proteins 
used in preincubation experiments are indicated by matching color 
scheme. Blocking data for WU ELISA–negative serum (C05) and 
KI ELISA–negative serum (C251) are shown for comparison. Toxo 
Mic,  microneme  protein  from  Toxoplasma  gondii;	 SV40,	 simian	
virus 40. Error bars indicate mean and SD. Serologic Evidence of WU and KI Polyomaviruses
Detection of Antibodies against WUPyV VP1  
and KIPyV VP1 by Western Blot
To  confirm  the  results  of  our  WU  ELISAs  and  KI   
ELISAs  and  further  assess  the  potential  serum  cross-
reactivity  with  VP1  proteins  of  related  polyomaviruses, 
we performed Western blot assays. The affinity purified 
GST-BKVP1 (69.3 kDa), GST-JCVP1 (68.8 kDa), GST-
KIPyV VP1 (70.7 kDa), GST-SV40VP1 (69.3 kDa), and 
GST-WUPyV VP1 (69.0 kDa), which all migrated to their 
relatively expected position in an SDS-polyacrylamide gel 
(Figure 4, panel A), were used as target antigens.
Hyperimmune rabbit serum against BKVLP reacted 
strongly with BKVP1 and SV40VP1 and, to a lesser extent, 
with JCVP1. Anti-JCVLP rabbit serum reacted strongly to 
both JCVP1 and BKVP1 but rather weakly to SV40VP1. 
These results were consistent with those of previous studies 
describing cross-reactivity among the VP1 of BKV, JCV, 
and  SV40  (19).  Neither  rabbit  serum  control,  however, 
showed any cross-reactivity to WUPyV VP1 or to KIPyV 
VP1 (Figure 4, panel B).
A set of human serum samples was randomly selected 
for confirmatory Western blotting. Figure 4, panels C and 
D, shows the results of 3 representative samples. They in-
cluded a sample that was positive by ELISA for antibod-
ies against WUPyV VP1 and KIPyV VP1 (S20), a sample 
that  was  ELISA  positive  for  WUPyV  but  negative  for   
KIPyV (C258), and a sample that was positive by ELISA for   
KIPyV and negative for WUPyV (C244). In each case, 
Western blot analysis corroborated the ELISA results.
Seroprevalence Rates
Overall WUPyV seropositivity in this cohort was 78.7% 
(330/419),  KIPyV  seropositivity  was  66.3%  (278/419), 
and seropositivity for both viruses was 60.1% (252/419) 
(Table). In general, the rate of WUPyV seropositivity was 
slightly higher than KIPyV seropositivity throughout. An-
tibodies against WUPyV and KIPyV appeared to be mater-
nally transmittable, on the basis of the high degree of sero-
positivity detected in the <6-month age group. The lowest 
seropositivity rates were observed for the age group 6 to 
<12 months (44.8% for WUPyV and 24.1% for KIPyV), 
consistent with the waning of maternal antibody levels. In-
fection rates for both viruses then increased rapidly, reach-
ing 86.7% for WUPyV and 93.3% for KIPyV in the 5-year 
age group. For patients >6 years of age, average WUPyV 
seropositivity was 80% (193/240). In this dataset, KIPyV 
infection appeared to peak in the age group 5–19 years (av-
erage seropositivity rate 93%), but in patients >20 years of 
age, the average was 70% (Figure 5).
Discussion
We  developed  WUPyV-specific  and  KIPyV-spe-
cific ELISAs to assess the extent of human infection by 
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Figure  4.  Results  of  patient  serum  sample  Western  blotting  for 
polyomaviruses.  A)  Coomassie  blue–stained  image  showing  5 
types	 of	 purified	 glutathione	 S-transferase	 (GST)–tagged	 viral	
protein	1	(VP1)	in	a	sodium	dodecyl	sulfate–polyacrylamide	gel.	
Lane	1,	GST-BKV	VP1;	lane	2,	GST-JCV	VP1;	lane	3,	GST–KI	
polyomavirus	(KIPyV)	VP1;	lane	4,	GST-SV40	VP1;	lane	5,	GST–
WU	 polyomavirus	 (WUPyV)	 VP1.	 B)	 Western	 blot	 results	 using	
control	rabbit	antiserum	against	BK	virus-like	particles	(BKVLP),	JC	
virus-like	particles	(JCVLP),	WUPyV	VP1,	or	KIPyV	VP1	as	primary	
antibody. C) Western blot results for serum that was positive (S20) 
for  WU  polyomavirus  and  KI  polyomavirus  by  ELISA. Antibody 
against GST was used as a loading control. D) Western blot result 
for serum that was ELISA positive for WU (C258) and KI (C244).RESEARCH
WUPyV  and  KIPyV.  Previous  studies  on  BKV,  JCV, 
and SV40 polyomaviruses indicated that the viral major 
capsid protein is immunodominant and that human serum 
can recognize the recombinant VP1 expressed in bacte-
ria  (16).  We  demonstrate  that  the  full-length  recombi-
nant WUPyV VP1 and KIPyV VP1 expressed in bacteria 
are capable of detecting antibodies against WUPyV and 
KIPyV VP1, respectively, using either the ELISA or the 
Western blot assay format.
One issue that has confounded serologic analysis of hu-
man polyomaviruses in the past is antigenic cross-reactivi-
ty (4,19). We performed a number of experiments to define 
whether cross-reactivity exists between antibodies against 
WUPyV VP1 in human serum and the VP1 antigens of 
KIPyV, SV40, BKV, and JCV. Preincubation experiments 
demonstrated that the GST-VP1 from BKV, JCV, and SV40 
reduced the absorbance signals only minimally, equivalent 
to the reduction observed when an irrelevant GST-fusion 
protein, GST-Mic, was used (Figure 3, panel A). These 
data indicate that BKV, JCV, and SV40 VP1s are not cross-
reactive with antibodies against WUPyV VP1. This obser-
vation was further substantiated by Western blotting using 
rabbit serum against virus-like particles of BKV and JCV, 
which yielded no detectable cross-reaction with WUPyV 
VP1 or KIPyV VP1. Because WUPyV VP1 and KIPyV 
VP1 share 65% sequence identity, potential cross-reactiv-
ity between them was a concern. However, preincubation 
with GST-KIPyV VP1 reduced the WU ELISA absorbance 
signal by only 13.5% on average, compared with 10.4% on 
average when an irrelevant GST protein or VP1 of BKV, 
JCV, and SV40 were used. Similarly, KI ELISA showed an 
average of 16.9% and 9.4% signal reduction when samples 
were preincubated with GST-WUPyV VP1 or GST-Mic 
protein, respectively.
As a separate line of evidence, Western blotting with 
serum that was positive for antibodies against WUPyV VP1 
and negative for antibodies against KIPyV VP1 (C258) and 
serum that was negative for WUPyV VP1 and  positive for 
KIPyV VP1 (C244) yielded no evidence of cross-reactivity 
(Figure 4, panel D). Collectively, the ELISA preincubation 
experiments and the Western blotting demonstrated mini-
mal, if any, detectable cross-reactivity between KIPyV and 
WUPyV within the sensitivity limits of these assays.
Our findings demonstrate high sustained rates of in-
fection by WUPyV and KIPyV in this cohort. Although 
the serum samples were selected by using broad inclusion 
criteria (specimen volume >0.5 mL) from patients visiting 
St. Louis Children’s Hospital and Barnes-Jewish Hospital, 
both tertiary referral hospitals, these results may be some-
what biased toward patients with some form of disease. 
Additional experiments with patient cohorts from different 
regions or with different inclusion criteria are necessary 
to generalize these results to the general population. The 
steep increase in seropositivity for WUPyV and KIPyV in 
patients 4–6 years of age raises the possibility that school 
attendance plays a role in facilitating transmission of these 
viruses. Serologic studies of other viruses such as bocav-
irus and BKV also showed elevated rates of infection in 
children of similar age (20–22). For KIPyV, the observed 
decrease in seropositivity rate for patients >19 years of age 
raises the possibility that antibodies against KIPyV wane 
over time. However, direct experimentation using longitu-
dinally collected serum would be necessary to address this 
possibility.
In conclusion, we have established WUPyV-specific 
and KIPyV-specific ELISAs using VP1 as the capture an-
tigen. We have demonstrated that cross-reactivity between 
antibodies against WUPyV VP1 (or KIPyV VP1) and VP1 
from KIPyV (or WUPyV), BKV, JCV, or SV40 viruses is 
minimal. We also demonstrated that WUPyV and KIPyV 
cause widespread infection in humans. These observations 
roughly parallel the extent of human exposure to BKV and 
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Figure	5.	Percentage	of	serum	samples	positive	for	antibodies	against	WU	polyomavirus	(WUPyV)	and	KI	polyomavirus	(KIPyV),	by	
patient age group.Serologic Evidence of WU and KI Polyomaviruses
JCV. Given that severe illnesses have been associated with 
infections by BKV and JCV, further studies are needed 
to determine whether WUPyV and KIPyV are similarly 
pathogenic.
Acknowledgments
We thank Steven Lawrence and Guang Wu for technical ad-
vice and support, and we thank Anne Gaynor for critical reading 
of the manuscript.
This work was supported in part by National Institutes of 
Health grant U54 AI057160 to the Midwest Regional Center of 
Excellence for Biodefense and Emerging Infectious Diseases Re-
search.
Dr  Nguyen  is  currently  a  senior  postdoctoral  fellow  at 
Washington University in St. Louis. His primary research focus 
is emerging infectious diseases with an emphasis on WU polyo-
mavirus.
References
  1.   Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu 
G, et al. Identification of a novel polyomavirus from patients with 
acute respiratory tract infections. PLoS Pathog. 2007;3:e64. DOI: 
10.1371/journal.ppat.0030064
  2.   Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, 
Persson MA, et al. Identification of a third human polyomavirus. J 
Virol. 2007;81:4130–6. DOI: 10.1128/JVI.00028-07
  3.   Rollison DE, Helzlsouer KJ, Alberg AJ, Hoffman S, Hou J, Daniel 
R, et al. Serum antibodies to JC virus, BK virus, simian virus 40, and 
the risk of incident adult astrocytic brain tumors. Cancer Epidemiol 
Biomarkers Prev. 2003;12:460–3.
  4.   Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor 
PD, et al. Lack of serologic evidence for prevalent simian virus 40 
infection in humans. J Natl Cancer Inst. 2003;95:1522–30.
  5.   Hou J, Major EO. Progressive multifocal leukoencephalopathy: JC 
virus induced demyelination in the immune compromised host. J 
Neurovirol. 2000;6:S98–100.
  6.   Limaye AP, Jerome KR, Kuhr CS, Ferrenberg J, Huang ML, Davis 
CL, et al. Quantitation of BK virus load in serum for the diagnosis 
of BK virus–associated nephropathy in renal transplant recipients. J 
Infect Dis. 2001;183:1669–72. DOI: 10.1086/320711
  7.   Arthur RR, Shah KV, Baust SJ, Santos GW, Saral R. Association of 
BK viruria with hemorrhagic cystitis in recipients of bone marrow 
transplants. N Engl J Med. 1986;315:230–4.
  8.   Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyo-
mavirus in human Merkel cell carcinoma. Science. 2008;319:1096–
100. DOI: 10.1126/science.1152586
  9.   Wattier RL, Vazquez M, Weibel C, Shapiro ED, Ferguson D, Lan-
dry ML, et al. Role of human polyomaviruses in respiratory tract 
disease in young children. Emerg Infect Dis. 2008;14:1766–8. DOI: 
10.3201/eid1411.080394
10.   Norja P, Ubillos I, Templeton K, Simmonds P. No evidence for an 
association between infections with WU and KI polyomaviruses and 
respiratory disease. J Clin Virol. 2007;40:307–11. DOI: 10.1016/j.
jcv.2007.09.008
11.   Han TH, Chung JY, Koo JW, Kim SW, Hwang ES. WU polyoma-
virus in children with acute lower respiratory tract infections, South 
Korea. Emerg Infect Dis. 2007;13:1766–8.
12.   Ren L, Gonzalez R, Xu X, Li J, Zhang J, Vernet G, et al. WU 
polyomavirus in fecal specimens of children with acute gastroen-
teritis,  China.  Emerg  Infect  Dis.  2009;15:134–5.  DOI:  10.3201/
eid1501.080693
13.   Mourez T, Bergeron A, Ribaud P, Scieux C, Peffault de Latour R, 
Tazi A, et al. Polyomaviruses KI and WU in immunocompromised 
patients with respiratory disease. Emerg Infect Dis. 2009;15:107–9. 
DOI: 10.3201/1501.080758
14.   Sharp CP, Norja P, Anthony I, Bell JE, Simmonds P. Reactivation 
and mutation of newly discovered WU, KI, and Merkel cell carcino-
ma polyomaviruses in immunosuppressed individuals. J Infect Dis. 
2009;199:398–404. DOI: 10.1086/596062
15.   Barbanti-Brodano G, Martini F, De Mattei M, Lazzarin L, Corallini 
A, Tognon M. BK and JC human polyomaviruses and simian virus 
40: natural history of infection in humans, experimental oncogenic-
ity, and association with human tumors. Adv Virus Res. 1998;50:69–
99. DOI: 10.1016/S0065-3527(08)60806-4
16.   Kjaerheim K, Røe OD, Waterboer T, Sehr P, Rizk R, Dai HY, et al. 
Absence of SV40 antibodies or DNA fragments in prediagnostic me-
sothelioma serum samples. Int J Cancer. 2007;120:2459–65. DOI: 
10.1002/ijc.22592
17.   Lundstig A, Eliasson L, Lehtinen M, Sasnauskas K, Koskela P, Dill-
ner J. Prevalence and stability of human serum antibodies to sim-
ian virus 40 VP1 virus-like particles. J Gen Virol. 2005;86:1703–8. 
DOI: 10.1099/vir.0.80783-0
18.   Jacobson R. Principles of validation of diagnostic assays for infec-
tious disease. Manual of standards for diagnostic tests and vaccines, 
3rd ed. Paris: Office International de Epizooties; 1996. p. 8–15.
19.   Viscidi  RP,  Rollison  DE,  Viscidi  E,  Clayman  B,  Rubalcaba  E, 
Daniel R, et al. Serological cross-reactivities between antibodies 
to simian virus 40, BK virus, and JC virus assessed by virus-like-
particle–based enzyme immunoassays. Clin Diagn Lab Immunol. 
2003;10:278–85.
20.   Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et 
al. Population-based study of antibody to the human polyomaviruses 
BKV and JCV and the simian polyomavirus SV40. J Med Virol. 
2003;71:115–23. DOI: 10.1002/jmv.10450
21.   Kahn JS, Kesebir D, Cotmore SF, D’Abramo A Jr, Cosby C, Weibel 
C, et al. Seroepidemiology of human bocavirus defined using re-
combinant virus-like particles. J Infect Dis. 2008;198:41–50. DOI: 
10.1086/588674
22.   Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepide-
miology of the human polyomaviruses. J Gen Virol. 2003;84:1499–
504. DOI: 10.1099/vir.0.18842-0
Address for correspondence: David Wang, Washington University in St. 
Louis, School of Medicine, Molecular Microbiology and Pathology and 
Immunology, 660 S Euclid Ave, Campus Box 8230, St. Louis, MO 63110, 
USA; email: davewang@borcim.wustl.edu
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	15,	No.	8,	August	2009	 1205 
Search past issues of EID at www.cdc.gov/eid